Tanke Biosciences Corp Financials

TNBI

FY2012 annual

Revenue $28.6M +19.8% YoY

Net Income -$210K +93.3% YoY

EPS (Diluted) Not reported for FY2012

Free Cash Flow -$2.0M -169.1% YoY

Source SEC Filings (10-K/10-Q) Data as of Sep 30, 2013 Currency USD FYE December

Tanke Biosciences Corp (TNBI) reported $28.6M in revenue for fiscal year 2012, up 19.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TNBI FY2012 2026-04-22

Growth did not translate into durable owner earnings because cash conversion and below-operating costs repeatedly interrupted improvement.

By FY2012, revenue was $28.6M versus $20.1M in FY2010, yet the company had shifted from cash-generative profits to a small loss and cash burn; that pairing points to cash conversion and below-operating costs, not demand, as the main constraint. The clearest sign is FY2012 itself: operating income reached $4.5M while operating cash flow was -$1.2M, so accounting improvement was not landing in the bank.

Gross margin was essentially flat between FY2010 and FY2011, but operating margin fell from 21.8% to 7.3%. Because the gross layer held steady while the operating layer compressed, the pressure looks more like overhead expansion than weaker core product economics; FY2012’s operating-margin rebound supports that reading.

The balance sheet became more short-term constrained: the current ratio fell from 5.3x to 1.8x by FY2012. At the same time, debt-to-equity stayed near 0.05x, so the strain was about liquidity cushion rather than heavy long-term borrowing.

Financial Health Signals

Financial health score pending refresh

We are recalculating Tanke Biosciences Corp's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Weak

3/9

Tanke Biosciences Corp passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Tanke Biosciences Corp reported a net loss of $210K while operations used $1.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage Adequate

3.13x

Tanke Biosciences Corp earns $3.13 in operating income for every $1 of interest expense ($4.5M vs $1.4M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$28.6M

YoY+19.8%

Tanke Biosciences Corp generated $28.6M in revenue in fiscal year 2012. This represents an increase of 19.8% from the prior year.

EBITDA

$5.2M

YoY+141.6%

Tanke Biosciences Corp's EBITDA was $5.2M in fiscal year 2012, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 141.6% from the prior year.

Net Income

-$210K

YoY+93.3%

Tanke Biosciences Corp reported -$210K in net income in fiscal year 2012. This represents an increase of 93.3% from the prior year.

EPS (Diluted)

Not reported for fiscal year 2012.

Cash & Balance Sheet

Free Cash Flow

-$2.0M

YoY-169.1%

Tanke Biosciences Corp recorded an outflow of $2.0M in free cash flow in fiscal year 2012, representing a cash shortfall after capex. This represents a decrease of 169.1% from the prior year.

Cash & Debt

$6.2M

YoY-19.9%

Tanke Biosciences Corp held $6.2M in cash against $793K in long-term debt as of fiscal year 2012.

Shares Outstanding

13M

YoY0.0%

Tanke Biosciences Corp had 13M shares outstanding in fiscal year 2012. That is unchanged from the prior year.

Dividends Per Share

Not reported for fiscal year 2012.

Margins & Returns

Gross Margin

34.8%

YoY-2.0pp

Tanke Biosciences Corp's gross margin was 34.8% in fiscal year 2012, indicating the percentage of revenue retained after direct costs. This is down 2.0 percentage points from the prior year.

Operating Margin

15.9%

YoY+8.6pp

Tanke Biosciences Corp's operating margin was 15.9% in fiscal year 2012, reflecting core business profitability. This is up 8.6 percentage points from the prior year.

Net Margin

-0.7%

YoY+12.4pp

Tanke Biosciences Corp's net profit margin was -0.7% in fiscal year 2012, showing the share of revenue converted to profit. This is up 12.4 percentage points from the prior year.

Return on Equity

-1.3%

YoY+18.4pp

Tanke Biosciences Corp's ROE was -1.3% in fiscal year 2012, measuring profit generated per dollar of shareholder equity. This is up 18.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$291K

YoY+18.1%

Tanke Biosciences Corp invested $291K in research and development in fiscal year 2012. This represents an increase of 18.1% from the prior year.

Capital Expenditures

$856K

YoY+22.2%

Tanke Biosciences Corp invested $856K in capex in fiscal year 2012, funding long-term assets and infrastructure. This represents an increase of 22.2% from the prior year.

Share Buybacks

Not reported for fiscal year 2012.

TNBI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

TNBI annual income statement

Metric	TTM	FY12	FY11	FY10	FY09
Revenue	$23.0M	$28.6M+19.8%	$23.8M+18.6%	$20.1M	N/A
Cost of Revenue	$15.5M	$18.6M+23.6%	$15.1M+18.6%	$12.7M	N/A
Gross Profit	$7.4M	$9.9M+13.4%	$8.8M+18.5%	$7.4M	N/A
R&D Expenses	N/A	$291K+18.1%	$246K	N/A	N/A
SG&A Expenses	$4.1M	$2.6M-42.7%	$4.5M+437.5%	$835K	N/A
Operating Income	-$57K	$4.5M+160.6%	$1.7M-60.2%	$4.4M	N/A
Interest Expense	$595K	$1.4M+6.2%	$1.4M+1258.1%	$100K	N/A
Income Tax	$238K	$832K+22.1%	$681K+17.0%	$582K	N/A
Net Income	-$1.6M	-$210K+93.3%	-$3.1M-214.5%	$2.7M+6.0%	$2.6M
EPS (Diluted)	—	N/A	-$0.24	$0.34	N/A

Metric	Q3'13	Q2'13	Q1'13	Q4'12	Q3'12	Q2'12	Q1'12	Q4'11
Revenue	$6.0M+8.3%	$5.6M+19.7%	$4.7M-30.3%	$6.7M-32.5%	$9.9M+33.3%	$7.4M+63.7%	$4.5M-31.8%	$6.7M
Cost of Revenue	$4.3M+15.9%	$3.8M+25.4%	$3.0M-32.7%	$4.5M-31.7%	$6.5M+39.0%	$4.7M+58.8%	$3.0M-31.7%	$4.3M
Gross Profit	$1.7M-7.2%	$1.8M+9.4%	$1.7M-25.4%	$2.2M-34.1%	$3.4M+23.5%	$2.7M+72.7%	$1.6M-31.8%	$2.3M
SG&A Expenses	$1.4M+36.2%	$997K+1.6%	$982K+26.4%	$776K+35.2%	$574K-15.6%	$680K+25.7%	$541K-12.2%	$616K
Operating Income	-$530K-454.3%	$150K+475.2%	-$40K-111.0%	$363K-83.4%	$2.2M+45.8%	$1.5M+206.5%	$489K-52.1%	$1.0M
Interest Expense	-$47K-218.3%	$39K-81.7%	$215K-44.5%	$387K+22.5%	$316K-14.2%	$369K-1.2%	$373K+375.0%	-$136K
Income Tax	-$27K-150.3%	$54K+66.7%	$32K-82.1%	$179K-19.6%	$223K-29.0%	$314K+168.6%	$117K-33.6%	$176K
Net Income	-$302K-355.6%	$118K+117.5%	-$676K+13.3%	-$780K-180.6%	$969K+255.6%	$272K+140.6%	-$671K-133.7%	$2.0M
EPS (Diluted)	N/A	N/A	N/A	N/A	$0.07+250.0%	$0.02+140.0%	-$0.05	N/A

TTM is the trailing twelve months, Q4 FY2012 through Q3 FY2013, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

TNBI Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

TNBI annual balance sheet

Metric	FY12	FY11	FY10	FY09
Total Assets	$28.8M+15.9%	$24.9M+87.6%	$13.3M	N/A
Current Assets	$22.4M+18.3%	$18.9M+146.5%	$7.7M	N/A
Cash & Equivalents	$6.2M-19.9%	$7.7M+246.5%	$2.2M+22.2%	$1.8M
Inventory	$1.4M+19.1%	$1.2M-12.3%	$1.4M	N/A
Accounts Receivable	$2.0M+3.6%	$1.9M+8.5%	$1.8M	N/A
Total Liabilities	$12.9M+43.1%	$9.0M+208.0%	$2.9M	N/A
Current Liabilities	$12.1M+241.1%	$3.5M+47.4%	$2.4M	N/A
Long-Term Debt	$793K+26.1%	$628K+38.7%	$453K	N/A
Total Equity	$15.8M-0.6%	$15.9M+94.2%	$8.2M+26.8%	$6.4M
Retained Earnings	$2.5M-7.8%	$2.7M-53.8%	$5.8M	N/A

Metric	Q3'13	Q2'13	Q1'13	Q4'12	Q3'12	Q2'12	Q1'12	Q4'11
Total Assets	$28.8M-2.2%	$29.5M+2.8%	$28.7M-0.7%	$28.8M0.0%	$28.8M+5.7%	$27.3M+11.6%	$24.5M-1.7%	$24.9M
Current Assets	$19.7M-10.1%	$21.9M+0.8%	$21.7M-2.8%	$22.4M+0.7%	$22.2M+7.5%	$20.7M+12.4%	$18.4M-2.9%	$18.9M
Cash & Equivalents	$5.1M+7.0%	$4.7M-15.4%	$5.6M-9.4%	$6.2M-44.1%	$11.0M+10.1%	$10.0M+31.4%	$7.6M-0.8%	$7.7M
Inventory	$1.6M-20.8%	$2.1M+49.1%	$1.4M-1.3%	$1.4M-13.6%	$1.6M+30.3%	$1.3M-7.6%	$1.4M+14.5%	$1.2M
Accounts Receivable	$2.8M+15.8%	$2.4M+29.2%	$1.8M-7.1%	$2.0M-12.7%	$2.3M+25.3%	$1.8M+5.5%	$1.7M-10.3%	$1.9M
Total Liabilities	$13.1M-3.6%	$13.6M+2.4%	$13.3M+2.7%	$12.9M+5.0%	$12.3M+5.9%	$11.6M+26.9%	$9.2M+1.4%	$9.0M
Current Liabilities	$12.2M-3.7%	$12.7M+7.7%	$11.8M-2.5%	$12.1M+8.4%	$11.2M+14.2%	$9.8M+10.8%	$8.8M+148.8%	$3.5M
Long-Term Debt	$733K-9.4%	$809K-43.6%	$1.4M+81.0%	$793K-16.4%	$948K-40.3%	$1.6M	$0-100.0%	$628K
Total Equity	$15.6M-1.0%	$15.7M+3.3%	$15.2M-3.5%	$15.8M-4.7%	$16.5M+5.5%	$15.7M+2.4%	$15.3M-3.5%	$15.9M
Retained Earnings	$1.6M-15.7%	$1.9M+6.5%	$1.8M-27.2%	$2.5M-23.9%	$3.3M+42.2%	$2.3M+13.5%	$2.0M-24.9%	$2.7M

Not reported in any period shown, so not listed: Goodwill.

TNBI Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

TNBI annual cash flow statement

Metric	TTM	FY12	FY11	FY10	FY09
Operating Cash Flow	-$3.6M	-$1.2M-132.4%	$3.7M-16.7%	$4.4M	N/A
Capital Expenditures	$2.5M	$856K+22.2%	$701K+821.5%	$76K	N/A
Free Cash Flow	-$6.1M	-$2.0M-169.1%	$3.0M-31.5%	$4.3M	N/A
Investing Cash Flow	-$2.4M	-$1.5M+58.4%	-$3.7M-30.0%	-$2.8M	N/A
Financing Cash Flow	-$95K	$1.1M-80.7%	$5.8M+576.4%	-$1.2M	N/A

Metric	Q3'13	Q2'13	Q1'13	Q4'12	Q3'12	Q2'12	Q1'12	Q4'11
Operating Cash Flow	$1.6M+1297.6%	-$135K-33.0%	-$101K+98.0%	-$5.0M-423.0%	$1.6M-12.2%	$1.8M+247.6%	$509K-30.4%	$731K
Capital Expenditures	$1.1M+75.0%	$613K-17.8%	$746K+1221.8%	$56K-86.3%	$412K+111.4%	$195K+0.6%	$194K-13.7%	$224K
Free Cash Flow	$538K+171.9%	-$748K+11.7%	-$847K+83.3%	-$5.1M-544.4%	$1.1M-27.5%	$1.6M+399.4%	$315K-37.8%	$507K
Investing Cash Flow	-$1.1M-67.7%	-$645K+13.5%	-$746K-754.1%	$114K+128.9%	-$394K+54.5%	-$866K-127.9%	-$380K+82.0%	-$2.1M
Financing Cash Flow	-$241K-51.5%	-$159K-169.2%	$230K+204.8%	$76K+268.1%	-$45K-103.2%	$1.4M+558.1%	-$305K+34.7%	-$466K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

TNBI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

TNBI annual financial ratios

Metric	FY12	FY11	FY10	FY09
Gross Margin	34.8%-2.0pp	36.8%0.0pp	36.8%	N/A
Operating Margin	15.9%+8.6pp	7.3%-14.5pp	21.8%	N/A
Net Margin	-0.7%+12.4pp	-13.2%-26.8pp	13.6%	N/A
Return on Equity	-1.3%+18.4pp	-19.8%-53.3pp	33.5%-6.6pp	40.2%
Return on Assets	-0.7%+11.9pp	-12.6%-33.2pp	20.6%	N/A
Current Ratio	1.85-3.5x	5.33+2.1x	3.19	N/A
Debt-to-Equity	0.050.0x	0.040.0x	0.06	N/A
FCF Margin	-7.1%-19.5pp	12.4%-9.1pp	21.4%	N/A

Metric	Q3'13	Q2'13	Q1'13	Q4'12	Q3'12	Q2'12	Q1'12	Q4'11
Gross Margin	28.0%-4.7pp	32.7%-3.1pp	35.8%+2.4pp	33.4%-0.8pp	34.2%-2.7pp	36.9%+1.9pp	35.0%0.0pp	35.0%
Operating Margin	-8.8%-11.5pp	2.7%+3.5pp	-0.9%-6.3pp	5.4%-16.6pp	22.0%+1.9pp	20.2%+9.4pp	10.8%-4.6pp	15.3%
Net Margin	-5.0%-7.1pp	2.1%+16.6pp	-14.5%-2.8pp	-11.7%-21.5pp	9.8%+6.1pp	3.7%+18.4pp	-14.8%-44.7pp	29.9%
Return on Equity	-1.9%-2.7pp	0.8%+5.2pp	-4.5%+0.5pp	-5.0%-10.8pp	5.9%+4.1pp	1.7%+6.1pp	-4.4%-16.9pp	12.5%
Return on Assets	-1.1%-1.5pp	0.4%+2.8pp	-2.4%+0.3pp	-2.7%-6.1pp	3.4%+2.4pp	1.0%+3.7pp	-2.7%-10.7pp	8.0%
Current Ratio	1.61-0.1x	1.73-0.1x	1.840.0x	1.85-0.1x	1.99-0.1x	2.110.0x	2.08-3.3x	5.33
Debt-to-Equity	0.050.0x	0.050.0x	0.090.0x	0.050.0x	0.060.0x	0.10+0.1x	0.000.0x	0.04
FCF Margin	8.9%+22.3pp	-13.4%+4.8pp	-18.2%+57.7pp	-75.8%-87.4pp	11.5%-9.7pp	21.2%+14.2pp	6.9%-0.7pp	7.6%

Similar Companies

Blockchain Loyal BBLC

$4.5M

Puget Technologies Inc PUGE

$949K

Alternaturals ANAS

$938K

Bluefire Equipme BLFR

$1.3M

American Graphit AGIN

$1.3M

Where Tanke Biosciences Corp Ranks

Frequently Asked Questions

What is Tanke Biosciences Corp's annual revenue?

Tanke Biosciences Corp (TNBI) reported $28.6M in total revenue for fiscal year 2012. This represents a 19.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Tanke Biosciences Corp's revenue growing?

Tanke Biosciences Corp (TNBI) revenue grew by 19.8% year-over-year, from $23.8M to $28.6M in fiscal year 2012.

Is Tanke Biosciences Corp profitable?

No, Tanke Biosciences Corp (TNBI) reported a net income of -$210K in fiscal year 2012, with a net profit margin of -0.7%.

What is Tanke Biosciences Corp's EBITDA?

Tanke Biosciences Corp (TNBI) had EBITDA of $5.2M in fiscal year 2012, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Tanke Biosciences Corp have?

As of fiscal year 2012, Tanke Biosciences Corp (TNBI) had $6.2M in cash and equivalents against $793K in long-term debt.

What is Tanke Biosciences Corp's gross margin?

Tanke Biosciences Corp (TNBI) had a gross margin of 34.8% in fiscal year 2012, indicating the percentage of revenue retained after direct costs of goods sold.

What is Tanke Biosciences Corp's operating margin?

Tanke Biosciences Corp (TNBI) had an operating margin of 15.9% in fiscal year 2012, reflecting the profitability of core business operations before interest and taxes.

What is Tanke Biosciences Corp's net profit margin?

Tanke Biosciences Corp (TNBI) had a net profit margin of -0.7% in fiscal year 2012, representing the share of revenue converted into profit after all expenses.

What is Tanke Biosciences Corp's return on equity (ROE)?

Tanke Biosciences Corp (TNBI) has a return on equity of -1.3% for fiscal year 2012, measuring how efficiently the company generates profit from shareholder equity.

What is Tanke Biosciences Corp's free cash flow?

Tanke Biosciences Corp (TNBI) recorded an outflow of $2.0M in free cash flow during fiscal year 2012. This represents a -169.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Tanke Biosciences Corp's operating cash flow?

Tanke Biosciences Corp (TNBI) recorded an outflow of $1.2M in operating cash flow during fiscal year 2012, representing cash used by core business activities.

What are Tanke Biosciences Corp's total assets?

Tanke Biosciences Corp (TNBI) had $28.8M in total assets as of fiscal year 2012, including both current and long-term assets.

What are Tanke Biosciences Corp's capital expenditures?

Tanke Biosciences Corp (TNBI) invested $856K in capital expenditures during fiscal year 2012, funding long-term assets and infrastructure.

How much does Tanke Biosciences Corp spend on research and development?

Tanke Biosciences Corp (TNBI) invested $291K in research and development during fiscal year 2012.

How many shares does Tanke Biosciences Corp have outstanding?

Tanke Biosciences Corp (TNBI) had 13M shares outstanding as of fiscal year 2012.

What is Tanke Biosciences Corp's current ratio?

Tanke Biosciences Corp (TNBI) had a current ratio of 1.85 as of fiscal year 2012, which is generally considered healthy.

What is Tanke Biosciences Corp's debt-to-equity ratio?

Tanke Biosciences Corp (TNBI) had a debt-to-equity ratio of 0.05 as of fiscal year 2012, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Tanke Biosciences Corp's return on assets (ROA)?

Tanke Biosciences Corp (TNBI) had a return on assets of -0.7% for fiscal year 2012, measuring how efficiently the company uses its assets to generate profit.

What is Tanke Biosciences Corp's cash runway?

Based on fiscal year 2012 data, Tanke Biosciences Corp (TNBI) had $6.2M in cash against an annual operating cash burn of $1.2M. This gives an estimated cash runway of approximately 63 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Tanke Biosciences Corp's Piotroski F-Score?

Tanke Biosciences Corp (TNBI) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Tanke Biosciences Corp's earnings high quality?

Tanke Biosciences Corp (TNBI) reported a net loss of $210K while operations used $1.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Tanke Biosciences Corp cover its interest payments?

Tanke Biosciences Corp (TNBI) has an interest coverage ratio of 3.13x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.